Get the Stockscreener App
1.13
13.08%
-0.17
Pds Biotechnology Corp stock is traded at $1.13, with a volume of 6.81M.
It is down -13.08% in the last 24 hours and up +14.07% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$1.30
Open:
$1.25
24h Volume:
6.81M
Relative Volume:
0.38
Market Cap:
$81.90M
Revenue:
Net Income/Loss:
$-33.36M
P/E Ratio:
-1.6851
EPS:
-0.6706
Net Cash Flow:
$-23.09M
1W Performance:
-18.12%
1M Performance:
+14.07%
6M Performance:
-11.72%
1Y Performance:
+19.50%
1-Day Range:
$1.0904
$1.26
1-Week Range:
$1.0904
$1.79
52-Week Range:
$0.1952
$1.79
Pds Biotechnology Corp Stock (PDSB) Company Profile
Name
Pds Biotechnology Corp
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
1.13 | 81.90M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corp Stock (PDSB) Latest News
Form S-3 PDS Biotechnology Corp For: 14 October By Investing.com - Investing.com Nigeria
Form S-3 PDS Biotechnology Corp For: 14 October By Investing.com - Investing.com India
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? - Zacks Investment Research
PDSB Jumps As PDS Biotechnology’s Phase 2 Data Impress And Nant Deal Reshapes Outlook - Timothy Sykes
PDS Biotechnology (NasdaqCM:PDSB) Stock Forecast & Analyst Predictions - Simply Wall Street
PDSB Stock Holds Gains As Volatile Surge Attracts Momentum Traders - StocksToTrade
A National Cancer Institute investigator will discuss an experimental treatment for colorectal cancer that spread to the liver. - Stock Titan
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
PDS Biotechnology gets 19.9% Nant Capital stake | PDSB SEC FilingForm SCHEDULE 13D - Stock Titan
Patrick Soon-Shiong backs PDS Biotechnology (NASDAQ: PDSB) as cancer drugs move toward Phase 3 - stocktitan.net
PDS Biotechnology Closes $11.3 Million Initial PIPE Tranche Led by Nant Capital - Minichart
PDS Biotechnology closes $11.3M private placement led by Soon-Shiong - Investing.com India
PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board - Quiver Quantitative
PDS Biotech Raises $11.3 Million in Initial PIPE Led by Patrick Soon-Shiong - citybiz
Patrick Soon-Shiong joins PDS Biotechnology (PDSB) board in up to $22M PIPE deal - Stock Titan
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors - Investing News Network
PDS Biotechnology closes $11.3M private placement led by Soon-Shiong - Investing.com
A cancer biotech raises $11.3 million. The Los Angeles Times owner joins its board. - stocktitan.net
PDS Biotechnology Market Sentiment - Benzinga España
PDSB Stock Jumps 36% on $22.55 Million PIPE—What the Dilution Math Says - TechStock²
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
Curious about the most active stocks on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure - Quiver Quantitative
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC - AllSci
PDS Biotech soars as it announces up to $22.55 million financing - The Pharma Letter
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - Benzinga
PDS Biotechnology Announces PIPE Financing and Strategic Alignment - TipRanks
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com Canada
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com India
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com
Phase 3 trial plan could unlock $11M more for PDS Biotechnology (NASDAQ: PDSB) - Stock Titan
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks - marketscreener.com
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
PDS Biotechnology Raises $22.6 Million in Equity Funding; Shares Rise - Yahoo Finance
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com UK
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDSB News | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology Corporation Approves Workforce Reduction - marketscreener.com
PDS Biotechnology (PDSB) to shed 36% of staff and part ways with COO - stocktitan.net
Park-Ohio (PKOH) insider still holds 870K shares after gift - Stock Titan
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com India
Pds Biotechnology Corp Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):